Clinical Trials Logo

Left Atrial Appendage Thrombosis clinical trials

View clinical trials related to Left Atrial Appendage Thrombosis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06232278 Not yet recruiting - Atrial Fibrillation Clinical Trials

Long-term Results of Percutaneous Left Atrial Closure at Brest University Hospital (CLAPOT)

CLAPOT
Start date: February 1, 2024
Phase:
Study type: Observational

Atrial Fibrillation represents an important risk of cardioembolic stroke. In more than 90% of cases, thrombus originate in the left atrial appendage. Therefore guidelines recommend the anticoagulation of patients with atrial fibrillation and a significant cardioembolic risk, predicted by the CHA2DS2VASc score. However, serious bleeding complications may definitively contraindicate the use of anticoagulants. For those patients, percutaneous Left Atrial Appendage Occlusion (LAAO) has became a recommended alternative to prevent the thrombus formation and reduce the risk of cardioembolic events. In the CHU of Brest, more than 120 patients have been treated with LAAO for the last 8 years with two different occluder devices : WATCHMAN®, Boston Scientifc and AMPLATZER Amulet®, Abbott Laboratories. This retrospective longitudinal observational study named CLAPOT (CHU of Brest' Left Atrial Appendage Percutaneous Occlusion Treatment) aims to evaluate the long term results of this procedure for effectiveness and safety and to compare the results between the two devices (Watchman and Amplatzer).

NCT ID: NCT06172738 Not yet recruiting - Clinical trials for Left Atrial Appendage Thrombosis

The Left Atrial Appendage Closure by Surgery and the Incidence of Stroke in Patients Undergoing Open-heart Surgery.

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

This study aims to assess the efficacy and safety of prophylactic surgical closure of the left atrial appendage for stroke and cardiovascular death prevention in patients undergoing open heart surgery, regardless of their preoperative AF status and stroke risk.

NCT ID: NCT04726943 Not yet recruiting - Atrial Fibrillation Clinical Trials

RF Applications for Residual LAA Leaks

REACT
Start date: February 1, 2021
Phase: N/A
Study type: Interventional

Although the clinical impact of residual left atrial appendage (LAA) leaks still requires confirmation, its patency resulting from incomplete LAA closure may promote blood stagnation and thrombus formation, and increase the risk of thromboembolic events. The main purpose of this trial is to evaluate the safety and efficacy of percutaneous leak closure with radiofrequency energy applications.

NCT ID: NCT04684212 Not yet recruiting - Atrial Fibrillation Clinical Trials

Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF

CORRAL-AF
Start date: December 1, 2024
Phase: N/A
Study type: Interventional

The primary objective is to demonstrate the safety and efficacy of the implantation of the LAmbre PlusTM device in patients with large or irregularly shaped appendages with non-valvular atrial fibrillation who are at increased risk for stroke and systemic embolism compared to oral anticoagulation (OAC).

NCT ID: NCT03792152 Not yet recruiting - Atrial Fibrillation Clinical Trials

A Trial of Rivaroxaban Versus Warfarin in Dissolving Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation

Start date: June 1, 2019
Phase: N/A
Study type: Interventional

The purpose of this clinical randomized trial is to evaluate the efficacy and safety of rivaroxaban compared with warfarin in dissolving the LAA thrombus in patients with atrial fibrillation.